Apr 30 2018
Celgene Topples on Report its MS Drug Could be Delayed by 3 Years
Mizuho | Investor's Business Daily
Apr 30 2018
Is Welltower’s Deal with ProMedica a Risky Venture or a Smart Move?
Mizuho | National Real Estate Investor
Apr 30 2018
Allergan Tops First-Quarter Views, But Dips on Report Its ‘Unlikely’ to Make a Deal
Mizuho | Investor's Business Daily
Apr 27 2018
What to Expect From Allergan, Aetna, Merck and Pfizer’s Earnings Next Week
Mizuho | TheStreet
Apr 26 2018
ViewPoints: Sloppiness not safety a big relief for Celgene’s ozanimod
Mizuho | FirstWord Pharma